Safety
diarrhoea, fatigue, chest pain, anemia
ADVERSE EFFECTS, ANEMIA
Seventy-two patients were evaluable for the safety analysis (Treatment-emergent AEs more than 10% incidence.Nineteen patients had a dose reduction in olaparib, and 14 patients had a dose reduction in ceralasertib. Six patients permanently discontinued treatment due to adverse effects; owing to diarrhoea, anemia requiring transfusion, chest pain, COVID-19, and fatigue (2 patients).